Literature DB >> 23945385

microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer.

Riccardo Cazzoli1, Fiamma Buttitta, Marta Di Nicola, Sara Malatesta, Antonio Marchetti, William N Rom, Harvey I Pass.   

Abstract

INTRODUCTION: Lung cancer is the highest cause of mortality among tumor pathologies worldwide. There are no validated techniques for an early detection of pulmonary cancer lesions other than low-dose helical computed tomography scan. Unfortunately, this method has some negative effects. Recent studies have laid the basis for development of exosomes-based techniques to screen/diagnose lung cancers. As the isolation of circulating exosomes is a minimally invasive procedure, this technique opens new possibilities for diagnostic applications.
METHODS: We used a first set of 30 plasma samples from as many patients, including 10 patients affected by lung adenocarcinomas, 10 with lung granulomas, and 10 healthy smokers matched for age and sex as negative controls. Wide-range microRNAs analysis (742 microRNAs) was performed by quantitative real time polymerase chain reaction. Data were compared on the basis of lesion characteristics, using WEKA software for statistics and modeling. Subsequently, selected microRNAs were evaluated on an independent larger group of samples (105 specimens: 50 lung adenocarcinomas, 30 lung granulomas, and 25 healthy smokers).
RESULTS: This analysis led to the selection of four microRNAs to perform a screening test (miR-378a, miR-379, miR-139-5p, and miR-200b-5p), useful to divide population into two groups: nodule (lung adenocarcinomas + carcinomas) and non-nodule (healthy former smokers). Six microRNAs (miR-151a-5p, miR-30a-3p, miR-200b-5p, miR-629, miR-100, and miR-154-3p) were selected for a second test on the nodule population to discriminate between lung adenocarcinoma and granuloma.
CONCLUSIONS: The screening test showed 97.5% sensitivity, 72.0% specificity, and area under the curve receiver operating characteristic of 90.8%. The diagnostic test had 96.0% sensitivity, 60.0% specificity, and area under the curve receiver operating characteristic of 76.0%. Further evaluation is needed to confirm the predictive power of these models on larger cohorts of samples.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23945385      PMCID: PMC4123222          DOI: 10.1097/JTO.0b013e318299ac32

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  34 in total

1.  Health care strategies to promote earlier presentation of symptomatic breast cancer: perspectives of women and family physicians.

Authors:  R Heisey; M Clemons; L Granek; K Fergus; S Hum; B Lord; D R McCready; B Fitzgerald
Journal:  Curr Oncol       Date:  2011-10       Impact factor: 3.677

2.  Accurate molecular classification of renal tumors using microRNA expression.

Authors:  Eddie Fridman; Zohar Dotan; Iris Barshack; Miriam Ben David; Avital Dov; Sarit Tabak; Orit Zion; Sima Benjamin; Hila Benjamin; Hagit Kuker; Camila Avivi; Kinneret Rosenblatt; Sylvie Polak-Charcon; Jacob Ramon; Nitzan Rosenfeld; Yael Spector
Journal:  J Mol Diagn       Date:  2010-07-01       Impact factor: 5.568

3.  Plasma microRNAs as novel biomarkers for early detection of lung cancer.

Authors:  Dali Zheng; Shadi Haddadin; Yong Wang; Li-Qun Gu; Michael C Perry; Carl E Freter; Michael X Wang
Journal:  Int J Clin Exp Pathol       Date:  2011-08-08

4.  MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer.

Authors:  Mattia Boeri; Carla Verri; Davide Conte; Luca Roz; Piergiorgio Modena; Federica Facchinetti; Elisa Calabrò; Carlo M Croce; Ugo Pastorino; Gabriella Sozzi
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-07       Impact factor: 11.205

Review 5.  Lung cancer screening.

Authors:  U Pastorino
Journal:  Br J Cancer       Date:  2010-04-27       Impact factor: 7.640

6.  Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells.

Authors:  Hadi Valadi; Karin Ekström; Apostolos Bossios; Margareta Sjöstrand; James J Lee; Jan O Lötvall
Journal:  Nat Cell Biol       Date:  2007-05-07       Impact factor: 28.824

7.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases.

Authors:  Xi Chen; Yi Ba; Lijia Ma; Xing Cai; Yuan Yin; Kehui Wang; Jigang Guo; Yujing Zhang; Jiangning Chen; Xing Guo; Qibin Li; Xiaoying Li; Wenjing Wang; Yan Zhang; Jin Wang; Xueyuan Jiang; Yang Xiang; Chen Xu; Pingping Zheng; Juanbin Zhang; Ruiqiang Li; Hongjie Zhang; Xiaobin Shang; Ting Gong; Guang Ning; Jun Wang; Ke Zen; Junfeng Zhang; Chen-Yu Zhang
Journal:  Cell Res       Date:  2008-10       Impact factor: 25.617

8.  Computed tomography screening and lung cancer outcomes.

Authors:  Peter B Bach; James R Jett; Ugo Pastorino; Melvyn S Tockman; Stephen J Swensen; Colin B Begg
Journal:  JAMA       Date:  2007-03-07       Impact factor: 56.272

9.  Breast cancer screening in the Czech Republic: time trends in performance indicators during the first seven years of the organised programme.

Authors:  Ondrej Majek; Jan Danes; Miroslava Skovajsova; Helena Bartonkova; Lucie Buresova; Daniel Klimes; Petr Brabec; Pavel Kozeny; Ladislav Dusek
Journal:  BMC Public Health       Date:  2011-05-10       Impact factor: 3.295

10.  Plasma microRNAs as potential biomarkers for non-small-cell lung cancer.

Authors:  Jun Shen; Nevins W Todd; Howard Zhang; Lei Yu; Xing Lingxiao; Yuping Mei; Maria Guarnera; Jipei Liao; Amy Chou; Changwan Larry Lu; Zhengran Jiang; HongBin Fang; Ruth L Katz; Feng Jiang
Journal:  Lab Invest       Date:  2010-11-29       Impact factor: 5.662

View more
  167 in total

1.  MicroRNAs level as an initial screening method for early-stage lung cancer: a bivariate diagnostic random-effects meta-analysis.

Authors:  Wen-Jie He; Wen-Hui Li; Bo Jiang; Yu-Feng Wang; Yao-Xiong Xia; Li Wang
Journal:  Int J Clin Exp Med       Date:  2015-08-15

Review 2.  Extracellular vesicles in breast cancer drug resistance and their clinical application.

Authors:  Shentong Yu; Yifang Wei; Yuqiao Xu; Yuan Zhang; Jipeng Li; Jian Zhang
Journal:  Tumour Biol       Date:  2016-01-21

3.  Reanalysis of microRNA expression profiles identifies novel biomarkers for hepatocellular carcinoma prognosis.

Authors:  Zhengqiang Wang; Qianshan Ding; Yanxia Li; Qingqing Liu; Wei Wu; Lu Wu; Honggang Yu
Journal:  Tumour Biol       Date:  2016-09-16

4.  Extensive miRNA expression analysis in craniopharyngiomas.

Authors:  Jill Samis; Elio F Vanin; Simone Treiger Sredni; Maria de Fátima de Bonaldo; Fabricio F Costa; Tadanori Tomita; Reema Habiby; Donald Zimmerman; Marcelo B Soares
Journal:  Childs Nerv Syst       Date:  2016-06-07       Impact factor: 1.475

5.  Correlation between serum exosome derived miR-208a and acute coronary syndrome.

Authors:  Shaojie Bi; Chunyan Wang; Yanwu Jin; Zhaopeng Lv; Xiaowei Xing; Qinghua Lu
Journal:  Int J Clin Exp Med       Date:  2015-03-15

Review 6.  Blood-based tumor biomarkers in lung cancer for detection and treatment.

Authors:  Hirva Mamdani; Shahid Ahmed; Samantha Armstrong; Tony Mok; Shadia I Jalal
Journal:  Transl Lung Cancer Res       Date:  2017-12

7.  Analysis of circulating non-coding RNAs in a non-invasive and cost-effective manner.

Authors:  Yu-Min Wang; Michael Patrick Trinh; Yongzan Zheng; Kaizhu Guo; Luis A Jimenez; Wenwan Zhong
Journal:  Trends Analyt Chem       Date:  2019-07-05       Impact factor: 12.296

Review 8.  The potential of tumor-derived exosomes for noninvasive cancer monitoring.

Authors:  Theresa L Whiteside
Journal:  Expert Rev Mol Diagn       Date:  2015-08-02       Impact factor: 5.225

9.  microRNAs and Prostate Cancer.

Authors:  Sajni Josson; Leland W K Chung; Murali Gururajan
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

Review 10.  Design and Analysis for Studying microRNAs in Human Disease: A Primer on -Omic Technologies.

Authors:  Viswam S Nair; Colin C Pritchard; Muneesh Tewari; John P A Ioannidis
Journal:  Am J Epidemiol       Date:  2014-06-24       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.